{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:38:07Z","timestamp":1768415887450,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clml.2016.08.011","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T14:50:29Z","timestamp":1470927029000},"page":"550-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis"],"prefix":"10.1016","volume":"16","author":[{"given":"Fernando","family":"Cabanillas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noridza","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wandaly I.","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.08.011_bib1","first-page":"168","article-title":"A\u00a0summary of the results of a review of 405 patients with non-Hodgkin's lymphoma at Stanford University","volume":"2","author":"Rosenberg","year":"1975","journal-title":"Br J Cancer Suppl"},{"key":"10.1016\/j.clml.2016.08.011_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjh.12667","article-title":"Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma","volume":"164","author":"Kedmi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.08.011_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3324\/haematol.10384","article-title":"The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma","volume":"92","author":"Koster","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.08.011_bib4","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1080\/1042819021000016050","article-title":"Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy","volume":"43","author":"Morabito","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.08.011_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.6004\/jnccn.2010.0023","article-title":"An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma","volume":"8","author":"Moskowitz","year":"2010","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2016.08.011_bib6","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1080\/10428190903093815","article-title":"Predicting transformation in follicular lymphoma","volume":"50","author":"de Jong","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.08.011_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.17219\/acem\/31804","article-title":"PET\/CT assessment of follicular lymphoma and high grade B cell lymphoma - good correlation with clinical and histological features at diagnosis","volume":"24","author":"Novelli","year":"2015","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.clml.2016.08.011_bib8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.pas.0000172191.87176.3b","article-title":"Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features","volume":"29","author":"Wang","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2016.08.011_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.08.011_bib10","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1200\/JCO.1997.15.8.2945","article-title":"Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival\u2013a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years","volume":"15","author":"Bastion","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib11","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","article-title":"Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma","volume":"14","author":"McLaughlin","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M","article-title":"An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute","volume":"52","author":"Garvin","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2016.08.011_bib14","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2004-04-1266","article-title":"Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma","volume":"104","author":"Coiffier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.011_bib15","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib16","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib17","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib18","article-title":"Stage IV indolent lymphoma: 25 years of treatment progress","volume":"102","author":"Liu","year":"2003","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2016.08.011_bib19","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study","volume":"30","author":"Rummel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3588.3588","article-title":"The baseline PET SUV correlates better with clinical outcome than the post-therapy PET scan in previously untreated patients with histologically aggressive non-Hodgkin lymphoma (NHL)","author":"Cabanillas","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.011_bib21","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00277-013-1991-y","article-title":"Survival of patients with transformed lymphoma in the rituximab era","volume":"93","author":"Guirguis","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2016.08.011_bib23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mds433","article-title":"Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy","volume":"24","author":"Bains","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8049","article-title":"Transformation of follicular lymphoma in the era of immunochemotherapy: a population-based study from British Columbia","volume":"30","author":"Al-Tourah","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.011_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/asheducation-2015.1.74","article-title":"What is the role of autologous transplant for lymphoma in the current era?","volume":"2015","author":"Stiff","year":"2015","journal-title":"Hematology"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016303858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016303858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:21Z","timestamp":1761870441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016303858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S2152265016303858"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.08.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}